Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis-Reference-Cited by-同舟云学术

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis

Published:2009-09-29 Issue:12 Volume:48 Page:1557-1559
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Quartuccio L.,Fabris M.,Salvin S.,Atzeni F.,Saracco M.,Benucci M.,Cimmino M.,Morassi P.,Masolini P.,Pellerito R.,Cutolo M.,Puttini P. S.,De Vita S.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/48/12/1557/5056296/kep314.pdf

Reference21 articles.

1. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register

2. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

3. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

4. B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost saving and predictive factors of response to rituximab in rheumatoid arthritis, including the IL-6 promoter gene polymorphism;Italian Journal of Public Health;2024-03-12

2. Comparative clinical characteristics of untreated early rheumatoid arthritis in patients with early and late onset according to the All-Russian Register of Patients with Arthritis “OREL”;Rheumatology Science and Practice;2022-02-27

3. La réponse aux antagonistes du récepteur de l’interleukine-6 dans la polyarthrite rhumatoïde est indépendante du nombre d’anti-TNF administrés auparavant : revue systématique et méta-analyse;Revue du Rhumatisme;2022-01

4. Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis;Frontiers in Medicine;2021-10-28

5. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey;JOINT BONE SPINE;2021